09.2024
Orbit Genomics was awarded a $2 million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer test. This test will be the second generation of OrbiSeq-L, a simple blood test that diagnoses lung cancer in patients that have indeterminate pulmonary nodules. The added subtyping capability will substantially expand the use of our test while improving patient outcomes, further reducing the need for biopsies, and significantly reducing costs.
Direct to Phase II (D2P2) is a Small Business Innovation Research (SBIR) award that allows small businesses to move directly into Phase II of research and development without receiving a Phase I award. This is possible if the business has already completed Phase I-like feasibility studies using other funding sources.
Dede Willis, CEO, says: “the grant review process featured an exceptionally rigorous peer reviewed evaluation of our technology platform by experts internal and external to NIH/NCI, providing robust validation of our scientific and business approach and its potential to drive innovation in the field.”
02.2024
Orbit Genomics, a Ventac Partners portfolio company, has been selected for the inaugural cohort of startups of the CancerX Accelerator program. For more information: https://orbitgenomics.com/2024/02/26/orbit-genomics-has-been-selected-for-the-inaugural-cohort-of-startups-in-cancerxs-accelerator-program/
12.2023
Ventac Partners portfolio company Orbit Genomics (www.orbitgenomics.com) is named A Deep Tech Pioneer by Hello Tomorrow. Out of an astonishing 4,500 applications from 120 countries, Orbit Genomics stood out as one of the most promising in the realm of deep tech. This prestigious recognition signifies a significant milestone in Orbit Genomics journey to transforming complex disease diagnosis, treatment, and prevention through early warning genomics. Orbit Genomics first target is early detection of lung cancer. For further information click here.
02.2023
We are very happy to see Ventac portfolio company Regenesance BV (dba Complement Pharma BV) publish a research article with Alexion, AstraZeneca Rare Disease in the J. of Innate Immunity. The paper describes the development and validation of a new humanized C6 monoclonal antibody that inhibits assembly of the membrane attack complex (MAC): a key part of the innate immune system. The antibody has potential to treat neuronal disease by preventing MAC formation and disease progression.
Research article: https://www.karger.com/Article/Pdf/524587
02.2023
We are delighted to see our portfolio company, RORA Biologics complete its exclusive license agreement with Case Western Reserve University (Cleveland, Ohio, USA) for cancer and HIV therapy technologies developed by its Chief Scientific Officer Dr. Rafick Sékaly. RORA-Bio is using this technology to develop potential treatments for certain cancers and people living with HIV.
01.2023
RhoVac has completed the acquisition of Chosa ApS in a reversed merger transaction, see enclosed press release.
01.2022
Ventac Partners portfolio company Orbit Genomics announced it has received $3 million in funding to launch its first product, OrbiSeq™ – L, a lung cancer diagnostic test with lead investors NHH Ventures and New Horizon Health Ltd (6606-HK). The company is raising an additional $1 million to complete the $4 million round. It also entered into an exclusive licensing agreement with New Horizon Health Ltd to market Orbit Genomics' products in Asia.” More information on this transaction is available at this link.
12.2021
APIM Therapeutics announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia University Irving Medical Center. The clinical study will investigate ATX-101 as single agent therapy for patients with leiomyosarcoma and liposarcoma who have received at least one prior treatment. For a copy of the corresponding press release, please follow this link.
11.2021
APIM Therapeutics announced today that the first patient has been treated with ATX-101 in the company's phase I/II ovarian cancer study. The clinical study investigates ATX-101 in combination with platinum-based chemotherapy and comprises two parts: Part 1 is a safety part with dose limiting toxicity as primary endpoint; Part 2 is an efficacy part with progression free survival as primary endpoint. For a copy of the corresponding press release, please follow this link.